{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:42:56Z","timestamp":1784198576856,"version":"3.55.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Painful diabetic peripheral neuropathy (PDPN) remains a serious complication of diabetes mellitus (DM). Recent clinical trials have demonstrated promising outcomes for pilavapadin (LX9211), an orally administered selective, potent inhibitor of adapter protein-2-associated kinase 1 (AAK1) and vixotrigine, a broad spectrum voltage-gated sodium channels (Navs) inhibitor. Their beneficial role was reflected in improved average daily pain (ADP) score and Patient Global Impression of Change (PGIC). Gamma-aminobutyric acid (GABA) receptor agonism has yielded favourable outcomes in preliminary studies. Experimental studies have further expanded the spectrum of potential agents, therapeutic targets and mechanisms in PDPN. Some of potential therapeutic approaches include chemokine suppression (CCR2\/CCR5 or CXCR1\/2 inhibition) and transient receptor potential vanilloid 1 (TRPV1) pathway suppression. Impaired mitochondrial function in PDPN is now being discussed and the inhibition of poly (adenosine diphosphate [ADP]-ribose) polymerase 1(PARP1), a mitochondrial enzyme responsible for deoxyribonucleic acid (DNA) repair is emerging. Local treatments have also been examined in animal models, such as resiniferatoxin. Limited evidence exists regarding the therapeutic potential of antidiabetic agents, glucagon-like peptide-1 receptor agonists (GLP-1RAs), being most widely studied in experimental settings. Future large clinical trials are now required to confirm the efficacy of novel promising agents and to delineate further potential favourable effects of antidiabetic agents in clinical settings.<\/jats:p>","DOI":"10.3389\/fendo.2026.1788702","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:14:19Z","timestamp":1774930459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["New pharmacological agents and emerging therapeutic targets for painful diabetic neuropathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Theodoros","family":"Panou","sequence":"first","affiliation":[{"name":"Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[{"name":"Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kempler","sequence":"additional","affiliation":[{"name":"Semmelweis University, Department of Medicine and Oncology","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-019-0097-9","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41582-024-01041-y","article-title":"The global and regional burden of diabetic peripheral neuropathy","volume":"21","author":"Savelieff","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110753","article-title":"The pathogenesis of painful diabetic neuropathy and clinical presentation","author":"Staehelin Jensen","year":"2023","journal-title":"Diabetes Res ClinPract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112099","article-title":"Prevalence and risk factors of painful diabetic neuropathy: A systematic review and meta-analysis","volume":"222","author":"Tao","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110602","article-title":"Prevalence of painful diabetic peripheral neuropathy in type 2 diabetes mellitus and diabetic peripheral neuropathy: A nationwide cross-sectional study in mainland China","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res ClinPract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06025-z","article-title":"Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study","volume":"67","author":"Elliott","year":"2024","journal-title":"Diabetologia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S012","article-title":"Retinopathy, neuropathy, and foot care: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110765","article-title":"Conventional management and current guidelines for painful diabetic neuropathy","author":"Tesfaye","year":"2023","journal-title":"Diabetes Res ClinPract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p866","article-title":"Combination therapy for painful diabetic neuropathy is safe and effective","volume":"381","author":"Saul","year":"2023","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01318-y","article-title":"monotherapy versus combination therapy in the treatment of painful diabetic neuropathy: a systematic review and meta-analysis","volume":"43","author":"Medeiros Dantas","year":"2023","journal-title":"Clin Drug Investig"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109928","article-title":"An overview of painful diabetic peripheral neuropathy: Diagnosis and treatment advancements","volume":"188","author":"Hagedorn","year":"2022","journal-title":"Diabetes Res ClinPract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","article-title":"Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: Report of the AAN guideline subcommittee","volume":"98","author":"Price","year":"2022","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S451006","article-title":"A systematic guideline by the ASPN workgroup on the evidence, education, and treatment algorithm for painful diabetic neuropathy: SWEET","volume":"17","author":"Sayed","year":"2024","journal-title":"J Pain Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13308","article-title":"Painful diabetic polyneuropathy","volume":"24","author":"Zuidema","year":"2024","journal-title":"Pain Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e4755","DOI":"10.1002\/ejp.4755","article-title":"E-52862-A selective sigma-1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double-blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy","volume":"29","author":"G\u00e1lvez","year":"2025","journal-title":"Eur J Pain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/17460441.2015.1051961","article-title":"Sigma-1 receptors and animal studies centered on pain and analgesia","volume":"10","author":"Davis","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1038\/s41467-024-49894-7","article-title":"Insight into binding of endogenous neurosteroid ligands to the sigma-1 receptor","volume":"15","author":"Fu","year":"2024","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human \u03c31 receptor","volume":"532","author":"Schmidt","year":"2016","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.7489","article-title":"Comparison of an emoji-based visual analog scale with a numeric rating scale for pain assessment","volume":"328","author":"He","year":"2022","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2425614","DOI":"10.1001\/jamanetworkopen.2024.25614","article-title":"GABA Analogue HSK16149 in Chinese patients with diabetic peripheral neuropathic pain: a phase 3 randomized clinical trial","volume":"7","author":"Guo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(87)91074-8","article-title":"The short-form mcGill pain questionnaire","volume":"30","author":"Melzack","year":"1987","journal-title":"Pain"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-008-9318-5","article-title":"Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods","volume":"17","author":"Janssen","year":"2008","journal-title":"Qual Life Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0188","article-title":"Efficacy and Safety of LX9211 for relief of diabetic peripheral neuropathic pain (RELIEF-DPN 1): results of a double-blind, randomized, placebo-controlled, proof-of-concept study","volume":"47","author":"Pop-Busui","year":"2024","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.235333","article-title":"Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain","volume":"358","author":"Kostich","year":"2016","journal-title":"J PharmacolExpTher"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c02131","article-title":"Discovery of (S)-1-((2\u2019,6-Bis(difluoromethyl)-[2,4\u2019-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176\/LX-9211): a highly selective, cns penetrable, and orally active adaptor protein-2 associated kinase 1 inhibitor in clinical trials for the treatment of neuropathic pain","volume":"65","author":"Luo","year":"2022","journal-title":"J Med Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.02.007","article-title":"Patients\u2019 impression of change following treatment for chronic pain: global, specific, a single dimension, or many","volume":"16","author":"Scott","year":"2015","journal-title":"J Pain"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/db25-1876-LB","article-title":"Pilavapadin, an oral, non-opioid, aak1 inhibitor for diabetic peripheral neuropathic pain (DPNP)\u2014results from a phase 2b, dose-ranging, randomized, multicenter study","volume":"74","author":"Pop-Busui","year":"2025","journal-title":"Diabetes"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106777","article-title":"Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy","volume":"197","author":"Hong","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1114","DOI":"10.1097\/PR9.0000000000001114","article-title":"A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy","volume":"8","author":"Michelson","year":"2023","journal-title":"Pain Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/17448069231218352","article-title":"Spinal HDAC6 mediates nociceptive behaviors induced by chronic constriction injury via neuronal activation and neuroinflammation","volume":"19","author":"Sun","year":"2023","journal-title":"Mol Pain"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03400-y","article-title":"Inhibition of histone deacetylase 6 alleviates neuropathic pain via direct regulating post-translation of spinal STAT3 and decreasing downstream C-C Motif Chemokine Ligand 7 synthesis","volume":"22","author":"Chi","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109803","article-title":"HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation","volume":"353","author":"Chen","year":"2022","journal-title":"ChemBiol Interact"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101971","article-title":"Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal study","volume":"59","author":"Faber","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/molpharm.120.000079","article-title":"Characterization of vixotrigine, a broad-spectrum voltage-gated sodium channel blocker","volume":"99","author":"Hinckley","year":"2021","journal-title":"MolPharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1989","article-title":"NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy-A randomized proof of concept study","volume":"26","author":"Tiecke","year":"2022","journal-title":"Eur J Pain"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1103","article-title":"First-in-human single-ascending-dose, multiple-dose, and food interaction studies of NRD.E1, an innovative nonopioid therapy for painful diabetic peripheral neuropathy","volume":"11","author":"Tiecke","year":"2022","journal-title":"ClinPharmacol Drug Dev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002470","article-title":"Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function","volume":"163","author":"Jain","year":"2022","journal-title":"Pain"},{"key":"B39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1152\/physrev.00005.2019","article-title":"mammalian transient receptor potential trpa1 channels: from structure to disease","volume":"100","author":"Talavera","year":"2020","journal-title":"Physiol Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129472","article-title":"DDD-028: A potent, neuroprotective, non-opioid compound for the treatment of diabetic neuropathy","volume":"95","author":"Micheli","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1346801","article-title":"J-2156, a small molecule somatostatin type 4 receptor agonist, alleviated hindpaw hypersensitivity in the streptozotocin-induced rat model of painful diabetic neuropathy but with a 2-fold decrease in potency at an advanced stage in the model, mimicking morphine","volume":"15","author":"Kuo","year":"2024","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.03.082","article-title":"Analgesic effects of the somatostatin sst4 receptor selective agonist J-2156 in acute and chronic pain models","volume":"539","author":"S\u00e1ndor","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120788","article-title":"Potentiation of morphine antinociception and inhibition of diabetic neuropathic pain by the multi-chemokine receptor antagonist peptide RAP-103","volume":"306","author":"Ruff","year":"2022","journal-title":"Life Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00186","article-title":"Preclinical evaluation of sigma 1 receptor antagonists as a novel treatment for painful diabetic neuropathy","volume":"7","author":"Peng","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4661519","article-title":"BHF177 suppresses diabetic neuropathic pain by blocking PKC\/CaMKII\/ERK1\/2\/CREB signaling pathway through activating GABAB receptor","volume":"2022","author":"Liu","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137410","article-title":"A new application for cenicriviroc, a dual CCR2\/CCR5 antagonist, in the treatment of painful diabetic neuropathy in a mouse model","volume":"25","author":"Bober","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4093\/dmj.2024.0504","article-title":"Effects of CXCR1\/2 blockade with ladarixin on streptozotocin-induced type 1 diabetes mellitus and peripheral neuropathy and retinopathy in rat","volume":"49","author":"Boccella","year":"2025","journal-title":"Diabetes Metab J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8547563","article-title":"CXCR4\/CX43 Regulate diabetic neuropathic pain via intercellular interactions between activated neurons and dysfunctional astrocytes during late phase of diabetes in rats and the effects of antioxidant N-Acetyl-L-Cysteine","volume":"2022","author":"Zhu","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.14670\/HH-18-405","article-title":"Upregulation of TLR9 may contribute to activation of microglia and painful diabetic neuropathy via the p38 MAPK pathway in rats","volume":"37","author":"Niu","year":"2022","journal-title":"HistolHistopathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214141","article-title":"Silencing P2X7R alleviates diabetic neuropathic pain involving TRPV1 via PKC\u03f5\/P38MAPK\/NF-\u03baBsignaling pathway in rats","volume":"23","author":"Chen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"eabh2557","DOI":"10.1126\/scitranslmed.abh2557","article-title":"GPR177 in A-fiber sensory neurons drives diabetic neuropathic pain via WNT-mediated TRPV1 activation","volume":"14","author":"Xie","year":"2022","journal-title":"SciTransl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0711","article-title":"GPR40 activation abolishes diabetes-induced painful neuropathy by suppressing VEGF-A expression","volume":"71","author":"K\u00f6nigs","year":"2022","journal-title":"Diabetes"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1113\/JP275067","article-title":"Diabetes-induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain","volume":"596","author":"Ved","year":"2018","journal-title":"J Physiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1400118","article-title":"The dual role of TRPV1 in peripheral neuropathic pain: pain switches caused by its sensitization or desensitization","volume":"17","author":"Gao","year":"2024","journal-title":"Front MolNeurosci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-9727-3","article-title":"Modulation of Diabetes-Induced Oxidative Stress, Apoptosis, and Ca2+ entry through TRPM2 and TRPV1 channels in dorsal root ganglion and hippocampus of diabetic rats by melatonin and selenium","volume":"54","author":"Kahya","year":"2017","journal-title":"MolNeurobiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2018.01.049","article-title":"Long non-coding RNA BC168687 is involved in TRPV1-mediated diabetic neuropathic pain in rats","volume":"374","author":"Liu","year":"2018","journal-title":"Neuroscience"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28818","article-title":"The role of orphan G protein-coupled receptors in pain","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002765","article-title":"Evaluation of a polymer-coated nanoparticle cream formulation of resiniferatoxin for the treatment of painful diabetic peripheral neuropathy","volume":"164","author":"Baskaran","year":"2023","journal-title":"Pain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10565-022-09702-8","article-title":"Alleviative effect of microRNA-497 on diabetic neuropathic pain in rats in relation to decreased USP15","volume":"39","author":"Zhang","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.109907","article-title":"Ginkgolide B can alleviate spinal cord glymphatic system dysfunction and provide neuroprotection in painful diabetic neuropathy rats by inhibiting matrix metalloproteinase-9","volume":"250","author":"Li","year":"2024","journal-title":"Neuropharmacology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1436146","article-title":"Liquiritin ameliorates painful diabetic neuropathy in SD rats by inhibiting NLRP3-MMP-9-mediated reversal of aquaporin-4 polarity in the glymphatic system","volume":"15","author":"Jia","year":"2024","journal-title":"Front Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.926128","article-title":"\u03b2-Hydroxybutyrate attenuates painful diabetic neuropathy via restoration of the aquaporin-4 polarity in the spinal glymphatic system","volume":"16","author":"Wang","year":"2022","journal-title":"Front Neurosci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15606","article-title":"Poly (ADP-ribose) polymerase 1-mediated defective mitophagy contributes to painful diabetic neuropathy in the db\/db model","volume":"162","author":"Yuan","year":"2022","journal-title":"J Neurochem"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002391","article-title":"Mitochondrial calcium uniporter deletion prevents painful diabetic neuropathy by restoring mitochondrial morphology and dynamics","volume":"163","author":"George","year":"2022","journal-title":"Pain"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3435","article-title":"Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited","volume":"54","author":"Obrosova","year":"2005","journal-title":"Diabetes"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2024.2431316","article-title":"siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model","volume":"33","author":"MoqbelRedhwan MA","year":"2025","journal-title":"J Drug Target"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109806","article-title":"Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia","volume":"186","author":"Zhang","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221857","article-title":"Semaglutide ameliorates diabetic neuropathic pain by inhibiting neuroinflammation in the spinal cord","volume":"13","author":"Lee","year":"2024","journal-title":"Cells"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108907","article-title":"The PPAR\u03b3 agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy","volume":"205","author":"Santos","year":"2022","journal-title":"Neuropharmacology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001856","article-title":"dosing time-dependent difference in the suppressive effect of empagliflozin on the development of mechanical pain hypersensitivity in diabetic mice","volume":"390","author":"Sato","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ejphar.2015.06.010","article-title":"Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin","volume":"764","author":"Ma","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2337\/db17-0503","article-title":"Negative regulation of TRPA1 by AMPK in primary sensory neurons as a potential mechanism of painful diabetic neuropathy","volume":"67","author":"Wang","year":"2018","journal-title":"Diabetes"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2021.147663","article-title":"Metformin attenuates diabetic neuropathic pain via AMPK\/NF-\u03baB signaling pathway in dorsal root ganglion of diabetic rats","volume":"1772","author":"Cao","year":"2021","journal-title":"Brain Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-018-2642-4","article-title":"Metformin attenuates increase of synaptic number in the rat spinal dorsal horn with painful diabetic neuropathy induced by type 2 diabetes: a stereological study","volume":"43","author":"Lin","year":"2018","journal-title":"Neurochem Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4703-13.2014","article-title":"Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity","volume":"34","author":"Gong","year":"2014","journal-title":"J Neurosci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bph.12895","article-title":"The non-peptide GLP-1 receptor agonist WB4\u201324 blocks inflammatory nociception by stimulating \u03b2-endorphin release from spinal microglia","volume":"172","author":"Fan","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13720","article-title":"Morroniside, a secoiridoid glycoside from Cornus officinalis, attenuates neuropathic pain by activation of spinal glucagon-like peptide-1 receptors","volume":"174","author":"Xu","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000320","article-title":"Lamiophlomis rotata, an orally available Tibetan herbal painkiller, specifically reduces pain hypersensitivity states through the activation of spinal glucagon-like peptide-1 receptors","volume":"121","author":"Zhu","year":"2014","journal-title":"Anesthesiology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1038\/s41598-018-21799-8","article-title":"Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain","volume":"8","author":"Kir\u00e1ly","year":"2018","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10091438","article-title":"Teneligliptin exerts antinociceptive effects in rat model of partial sciatic nerve transection induced neuropathic pain","volume":"10","author":"Kuthati","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.11.006","article-title":"Pioglitazone inhibits the development of hyperalgesia and sensitization of spinal nociresponsive neurons in type 2 diabetes","volume":"17","author":"Griggs","year":"2016","journal-title":"J Pain"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial","volume":"400","author":"Tesfaye","year":"2022","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(23)00003-X","article-title":"Who really benefits from drug combinations and long titrations for pain","volume":"401","author":"Perry","year":"2023","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109063","article-title":"Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations","volume":"186","author":"Ziegler","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06529-w","article-title":"Beyond pain relief: the effects of chronic opioid use on brain structure and function in diabetic neuropathy-a multimodal neuroimaging study","volume":"68","author":"Sloan","year":"2025","journal-title":"Diabetologia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0884-5_17","article-title":"mechanical nociception in mice and rats: measurement with automated von frey equipment","volume":"2201","author":"Campana","year":"2021","journal-title":"Methods Mol Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneumeth.2015.08.010","article-title":"Practical mechanical threshold estimation in rodents using von Frey hairs\/Semmes-Weinstein monofilaments: Towards a rational method","volume":"255","author":"Bradman","year":"2015","journal-title":"J Neurosci Methods"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12977","article-title":"Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor","volume":"14","author":"Kessler","year":"2021","journal-title":"Clin Transl Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1788702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:14:22Z","timestamp":1774930462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1788702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":91,"alternative-id":["10.3389\/fendo.2026.1788702"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1788702","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1788702"}}